TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Failure in CNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) >= 20 mcg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients completing a full course of blinatumomab post-auto-SCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rheumatoid factor (RF) antibody status and concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-CCP antibody status and concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evidence of radiographic erosions and scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anxiolytic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sperm detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Facial corrugator EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Total MADRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of intestinal speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Knowledge Survey
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PedsQL Family Impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative vasopressor usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative faecal output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in clinical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in psychosocial outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annual incident declaration rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Capacity of the DASI self-questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose-per-fraction based on acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate at the end of study treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity at the end of study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the number of household contacts initiating treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effects of intervention on prostate-specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the First Recurrence of Uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Toxicity Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: extubation set tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Itch Numeric Rating Scale scores (I-NRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WCST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TMT-A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation between PET/MR imaging results and Alzheimer's disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Days to first psychiatric appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall psychiatric counseling attendance compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Psychiatrist session attendance compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Individual and group psychiatric session attendance compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in average 24-hour heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesic consumption (mg)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Body temperature degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral bioavailability (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in detected paraben levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder pain and disability Index (SPADI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ROM Shoulder Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of new cerebral dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confirmed, Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritation Evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Exclusive Breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Change From Baseline in Time Weighted Average Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Inhalation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of diabetes medication changes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of developing cerebral palsy at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Microcirculation of the caput femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-diphteria (Anti-D) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-tetanus (Anti-T) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-pertussis Toxoid (Anti-PT) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-pertactin (Anti-PRN) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of severe anemia (Hb < 7 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cure of severe anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Endogenous pain modulation mechanisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in serum creatinine (SCr) 0.5 mg/dL from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Morphologic changes in psoriatic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Patients Continuing Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants who had thrombo-embolic event
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of Atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose
Endpoint domain: Physiological/clinical
Primary endpoint: Isometric voluntary muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medical care modalities satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of rotavirus related hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frequency of patients receiving parenteral nutrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: seizure outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Major Complications After an Attempted ADO II AS Device Implant
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Effective Closure of the Ductus Arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dry mouth evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the log10 Transformed Sum of Product of Diameters (SPD) in the Index Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Percentage of naïve B Cells Out of Total B Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change overtime of Olerud and Molander Ankle Score (OMAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Position Outcome Radiographic Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Unplanned Surgery at the Operative Site
Endpoint domain: Adverse events/effects
Primary endpoint: Device-Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of Actinic Keratosis (AK) lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: myocardial infarcted size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of habitual physical activity in hours/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Keloid Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gastric Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dose Normalized AUC (0-t) [AUC (0-t)dn]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the 37-item version of the Mini-Mental State Examination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Center for Epidemiologic Studies Depression Scale (CES-D) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Six-object memory recall test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in total score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of estrogen deficiency symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Menopause-related quality of life (MENQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance with AF/AH treatment guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Infants Infected with Hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Congenital Defects and/or Malformation Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of bilirubin's value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HRQOL in adult patients with hematologic malignancies
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptoms in adult patients with hematologic malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to therapy in adult patients with hematologic malignancies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of the bud
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with undetectable HIV-1 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with certain adverse events related to the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of UCN-01
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Long term success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of clue cells quantified by fresh cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of vaginal pH measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of bacterial vaginosis by culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Device and/or Procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of Levonorgestrel: area under the concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacokinetics of ethinyl estradiol: area under the concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self-Injurious Thoughts and Behaviors Inventory (SITBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Tolerated Dose (MTD) of Oral L-T3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower beta hydroxybutyrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seizure Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the severity of binge-eating disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average cost hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Sputum Myeloperoxidase (MPO) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of SRX246
Endpoint domain: Adverse events/effects
Primary endpoint: Transcutaneous Bilirubin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of absolute neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum absolute neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brain constructure and neural network changes one day after shunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain constructure and neural network changes 90 days after shunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain constructure and neural network changes one year after shunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of device related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient adherence to treatment plan
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with systemic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of complications during the follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients developing a lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abdominal pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With TEAEs, SAEs, and Severe TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Discontinuations From Study/Study Drug or Dose Reduction Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Summary of Baseline and Change From Baseline in Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in muscle quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle adipose infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of endotoxin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration at steady state (Css,max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-time (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All observed or reported AEs (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: HBsAg change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of healed chronic wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change in Estimated Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Treatment Success at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effects of incorporating PHWP into diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Explicit Affect Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implicit Affect Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial clinical scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in DLQI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in mean Borg Dyspnoea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Curve (AUC) of Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aβ40 and Aβ42 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ad libitum Snack Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ad libitum Food Category Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects remaining on methotrexate without intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: FEV₁ AUC (0 -6 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Postural sway score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological morbidity and distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of VAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of globus complaint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective acceptance of hearing aid setting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status